Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

One of our scientists, Dr Hannah Bolland, has become a virtual teacher, connecting school students with science.

Dr Hannah Bolland is a post-doctoral researcher working with Professor Ester Hammond, and has also taken on the role as a biology teacher with AimHi.

Hannah was selected to give a series of video lessons to students from around the world. The first lesson, ‘What is Cancer’, streamed live on 27 May and is still available on the AimHi YouTube Channel.

In 28 mins, Hannah explored the Hayflick limit, mutations, the growth of cancer and even some pathology slides. The students were constantly engaged contributing comments through the chat feature. Her session ends with why we should love naked mole rats! 

Hannah did a fantastic job, introducing new material, annotating live on the slide, and responding to questions in the interactive  chat feature. The lesson was a dynamic mixture of ideas, pictures, audience input, and quizzes. Hannah’s next session will talk about diagnosis.

 

 

 

 

 

 

AimHi

AimHi was started by Matthew Shribman, former PhD student at Oxford’s Department of Chemistry, and Henry Waite, an Oxford chemistry graduate.

Aware that schools were closing round the world, they set out to put students in contact with exceptional teachers with expert knowledge. School students are provided with the chance to interact with scientists and explore topics from space to dinosaurs, and, in Hannah’s case, cancer.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.